Cosmo and Glenmark receives market authorization of Winlevi in Europe

Winlevi is authorized in EU for the treatment of acne vulgaris

Neurocrine review highlights key differences between tardive dyskinesia drugs

Rafa Laboratories lands $186 million BARDA contract to develop life-saving trauma drug

Landmark studies have shown that rapid TXA administration can significantly reduce mortality

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan

Roche wins EU green light for one-minute injection cancer therapy

FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer

HER2-mutant NSCLC typically has a poor prognosis and limited treatment options

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic

Merck’s two-drug HIV regimen hits phase 3 success

The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks

Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment

This is the first and only subcutaneous immune checkpoint inhibitor available in Europe